You are here

CSF Tau Biomarker-guided Development of Hsp90 Inhibitors for Alzheimer's Disease

Award Information
Agency: Department of Health and Human Services
Branch: National Institutes of Health
Contract: 1R41AG042205-01
Agency Tracking Number: R41AG042205
Amount: $200,752.00
Phase: Phase I
Program: STTR
Solicitation Topic Code: NIA
Solicitation Number: PA11-097
Timeline
Solicitation Year: 2012
Award Year: 2012
Award Start Date (Proposal Award Date): N/A
Award End Date (Contract End Date): N/A
Small Business Information
1770 Massachusetts Avenue, Suite 170
Cambridge, MA 02140-
United States
DUNS: 831491571
HUBZone Owned: No
Woman Owned: Yes
Socially and Economically Disadvantaged: No
Principal Investigator
 YUKARI PERRELLA
 (617) 953-4618
 yukari.y.perrella@yumatherapeutics.com
Business Contact
 YUKARI PERRELLA
Phone: (617) 953-4618
Email: yukari.y.perrella@yumatherapeutics.com
Research Institution
 BRIGHAM AND WOMEN'S HOSPITAL
 
BRIGHAM AND WOMEN'S HOSPITAL RESEARCH ADMINISTRATION 75 FRANCIS ST
BOSTON, MA 02115-
United States

 () -
 Domestic Nonprofit Research Organization
Abstract

DESCRIPTION (provided by applicant): Research and Related Other Project Information Item 7. Project Summary/Abstract Neurodegeneration in Alzheimer's disease (AD) may result from deposition of A as plaques in brain tissue. However, less effort has been made to elucidate the role of tau- containing neurofibrillary tangles (NFTs) in AD. Accumulating evidence suggests that tau containing NFTs is an important component in the initiation and progression of AD and other neurodegenerative diseases. In this proposal the tau pathway is targeted through inhibition of the molecular chaperone Hsp90 as a promising new approach to affect the disease progression of AD. The goal of this grant is to optimize two structurally distinct scaffolds aided by in silico modeling and physical-chemical property predictions in order to generate novel brain permeable Hsp90 inhibitors as AD therapeutics. Subsequently, these compounds will be clinically developed for the treatment of AD using CSF biomarkers, as well as improved cognition,for in vivo efficacy determinations. PUBLIC HEALTH RELEVANCE: Research and Related Other Project Information Item 8. Project Narrative This research is focused on identifying potential drug candidates to treat Alzheimer's disease (AD) and in thisway it addresses NIA's priorities to support research on health and disease in the aged. Furthermore, this project targets the tau pathway as a promising new approach to affect the disease progression of AD.

* Information listed above is at the time of submission. *

US Flag An Official Website of the United States Government